title: CDIP-2, a synthetic peptide derived from chemokine (C-C motif) ligand 13 (CCL13), ameliorates allergic airway inflammation.
abstract: Airway inflammation is characterized by selective recruitment of mononuclear and granulocytic cells. This recruitment is mediated by the action of chemotactic cytokines, such as chemokines. A number of chemokines and their receptors have been identified and proposed as potential therapeutic agents in allergic airway inflammation. One of these chemokines is chemokine (C-C motif) ligand 13 (CCL13), a CC chemokine that has been associated with allergic inflammatory diseases such as asthma and allergic rhinitis. To investigate alternative therapeutic agents to alleviate allergic inflammatory diseases, a number of chemokine-derived synthetic peptides were designed and tested for their ability to modulate in vitro and in vivo chemokine-mediated functions. Our results show that one of these peptides, CDIP-2, displayed antagonist functions in in vitro chemotaxis assays using monocytic cell lines. In addition, we found that CDIP-2 significantly reduced peribronchial, perivascular infiltrate and mucus overproduction in an ovalbumin-induced allergic lung inflammation murine model. Thus, CDIP-2 may be considered as part of a novel group of anti-inflammatory agents based on chemokine-derived synthetic peptides.
authors.affiliation: Departamento de Inmunologia, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México.
authors.forename: E
authors.initials: E
authors.lastname: Mendez-Enriquez
authors.forename: Y
authors.initials: Y
authors.lastname: Melendez
authors.forename: F
authors.initials: F
authors.lastname: Martinez
authors.forename: G
authors.initials: G
authors.lastname: Baay
authors.forename: S
authors.initials: S
authors.lastname: Huerta-Yepez
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez-Bonilla
authors.forename: T I
authors.initials: TI
authors.lastname: Fortoul
authors.forename: G
authors.initials: G
authors.lastname: Soldevila
authors.forename: E A
authors.initials: EA
authors.lastname: García-Zepeda
mesh_terms: D000818:Animals; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D018945:Monocyte Chemoattractant Proteins / Q000276:immunology*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D010047:Ovalbumin; D010455:Peptides / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D010538:Peritonitis / Q000188:drug therapy; D012130:Respiratory Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: C099677:CCL13 protein, human; C529302:CDIP-2 peptide; D016207:Cytokines; D007074:Immunoglobulin G; D018945:Monocyte Chemoattractant Proteins; D010455:Peptides; D010047:Ovalbumin